



The source for tools and information for NGOC Employees

NGOC Clinical Trials List - Printable Version

Head and Neck (C00-C14) - Locally Advanced 1st Line Recurrent / Metastatic - Previously Treated	
Esophagus/Gastric (C15-C16) - Stage II- IV, Neo-adjuvant - First Line, Recurrent or Metastatic AZ D702AC00001 (Artemide-Gastric01) A Phase 3 Study of Rilvegostomig in Combination with Fluoropyrimidine - Arm A: Rilvegostomig + T-Dxd + Investigator's Choice: 5-FU or Capecitabine - Arm B: Pembro + trastuzumab + Investigator's choice: Cisplatin+ 5FU or CAPOX+capecitabine - Arm C: Rilvegostomic (750mg IV Q3w) + Trastuzumab + Investigator's Choice: Cisplatin+5FU OR CAPOX+Capecitabine - Previously Treated AZ D9802C00001 (Clarity) AZD0901 compared with Investigator's choice of therapy in participants - Arm 1: AZD0901 2.2 mg/kg IV Q3W - CLOSED - Arm 2: AZD0901 1.8 mg/kg IV Q3W - Arm 3: Investigator's choice of therapy (ramucirumab, paclitaxel, docetaxel, irinotecan, TAS-102, and apatinib)	
Biliary (K83.9) First Line Therapy	
Pancreas (C25) - Adjuvant / NeoAdjuvant 1st Line, Metastatic BMS CA240-0030 (MountainTAP) Study of BMS-986504 in Combination with Nab-p/Gem versus Placebo in Co - Phase 2 Dose Selection Arm A: BMS-986504 400mg + Nab-Pac + Gem - Phase 2 Dose Selection Arm B: BMS-986504 600mg + Nab-Pac + Gem - Phase 2 Dose Selection Arm C: BMS-986504 400mg Placebo + Nab-Pac + Gem - Phase 2 Dose Selection Arm D: BMS-986504 600mg Placebo + Nab-Pac + Gem - NOT YET OPEN Phase 3 Arm E: BMS-986504 Optimal Dose + Nab-Pac + Gem - NOT YET OPEN Phase 3 Arm F: BMS-986504 Optimal Dose Placebo + Nab-Pac + Gem - Previously Treated	
Colon & Rectum (C18-C20) - Stage III, Resected Colon, Adjuvant - Stage IV, Metastatic, 1st Line, Colon or Rectum - Metastatic, 3rd Line, Colon AbbVie M24-064 Phase 3 comparing Abbv-400 Monotherapy vs Lonsurf+Bevacizumab in subj - CLOSED: Stage 1 Arm A: AbbV-400 2.0mg/kg IV Q3W - CLOSED: Stage 1 Arm B: AbbV-400 2.4mg/kg IV Q3W - NOT OPEN Stage 2 Arm A: AbbV-400 Optimal Dose IV Q3W - NOT OPEN Stage 2 Arm B: LONSURF 35mg/m2 PO BID + Bevacizumab 5mg/kg IV q2w - Metastatic 2nd or 3rd Line, KRAS Mutated - Metastatic 2nd or 3rd Line, KRAS Wild Type - Refractory	
Lung, Squamous Cell (C34) - Stage IV, Metastatic - Second Line	
Lung, Non-Small Cell (C34) - Stage IB, II, IIIA; Adjuvant - Stage IB, II, Resectable IIIA - Stage II-III Resected - Stage IIIA-IIIB, Locally Advanced, Unresectable - Stage IIB-IIIB Resected and Chemotherapy-Naive Stage IV - First Line- Metastatic - Stage IV, Metastatic 2nd or 3rd Line - Metastatic, Previously Treated MK-2870-004 Phase 3 Study of MK-2870 vs Chemo Previously Treated Advanced or Metas - Arm A: MK-2870 4mg/KG IV Days 1,15, & 29 every 6 week cycle - Arm B: Investigator's choice of Docetaxel 75mg/m2 IV or Pemetrexed 500mg/m2 IV on Days 1 and 22 of 6 week cycle AbbV M25-274 (TELmet NSCLC-04) A Phase 2, Open-Label, Randomized, Global Study of Three Telisotuzumab - Arm A: Telisotuzumab vedotin 1.9 mg/kg Q2W - Arm B: Telisotuzumab vedotin 1.6 mg/kg Q2W - Arm C: Telisotuzumab vedotin 1.6 mg/kg Q2W x 4 cycles then 1.9 mg/kg Q2W AZ D7630C00001 (TROPION-Lung17) Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-posit - Arm A: Dato-DXd 6mg/kg IV q3w - Arm B: Docetaxel 75mg/m2 IV q3w	
Mesothelioma (C45)	
Lung, Small Cell (C34) - Extensive Stage, Small Cell Lung Ca BMS CA245-0001 A Randomized, Double-Blind, Multicenter Phase 3 Trial - Arm A:BMS-986489 420mg/nivolumab 360 mg IV+carboplatin+etoposide - Arm B: atezolizumab 1200mg IV+carboplatin+etoposide - Previously Treated	
Breast, Adjuvant (C50) - NeoAdjuvant, Stage I, II, III - Adjuvant GS-US-595-6184 (ASCENT-05) A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govite - Arm A: Sacituzumab Govitecan 10mg/kg IV Days 1 and 8 + Pembrolizumab 200mg IV Day 1 Q3W X 8 cycles - Arm B: Treatment of Physician's Choice: Pembrolizumab 200mg IV Day 1 Q3 weeks X 8 cycles OR Pembrolizumab 200 mg IV Day 1 and Capecitabine 1000 mg/m2 PO BID D1-D14 Q3 Weeks X 8 cycles	
Breast, Her-2 Positive (C50) - NeoAdjuvant HER-2 Positive - Adjuvant, HER-2 Positive - Metastatic, HER-2 Positive, 1st Line - Metastatic, Previously Treated, Her-2 Positive	
Breast, Advanced (C50) - Stage IV, Metastatic, 1st Line RGN WO45654 (INAVO123) A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED - Arm A: Inavolisib 9mg tablet PO QD days 1-28 of 28 day cycle + palbociclib 125mg PO QD D1-21 of 28 + letrozole 2.5mg PO QD - Arm B: Placebo tablet PO QD days 1-28 of 28 day cycle + palbociclib 125mg PO QD D1-21 of 28 + letrozole 2.5mg PO QD - Stage IV, Metastatic, ER - - Stage IV, Metastatic, Previously Treated - Stage IV, Metastatic, Triple Negative Breast Cancer	
Breast, ER Positive (C50) - Adjuvant AZ D8535C00001 (Cambria 2) Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER - Arm A: Standard ET (AI or tamoxifen)+/-abemaciclib (+/-LHRH agonist*) - Arm B: Camizestrant 75 mg/daily +/- abemaciclib (+/- LHRH agonist*) - Metastatic, First Line - Metastatic, Prior Hormonal Therapy	
Melanoma (C43) - Adjuvant - Locally advanced or Metastatic - Previously Treated	
Ovarian (C56) Previously Treated	
Bladder (C67) - Urothelial	
Renal (C64) - Adjuvant, Phase III - First Line Treatment, Advanced or Metastatic - Advanced, Metastatic - Previously Treated	
Prostate (C61) - Hormone Refractory, 1st Line 1st line Metastatic - Metastatic, 2nd Line Prostate - Hormone Refractory; Bone Predominant 3rd Line or Greater	
Sarcoma (C46-C49) Sarcoma, Previously Treated	
Adrenal (C74) Previously Treated	
Lymphoma (C82-C88) Indolent, previously treated	

- 2. Follicular, First Line
- 3. Indolent, Relapsed
- 4. Relapsed or Refractory, DLBCL, FL
- 5. Large Cell Lymphoma, Relapsed/Refractory
- 6. Relapsed and Refractory Follicular Lymphoma
 - a. **BMS CA073-1003 A Phase 3, Multicenter, Randomized, Open Label Study to Compare the Ef**
 - i. Arm A: R-Golca 0.4mg D1-14/48 days+Rituximab x5cycles followed by golcadomide monotherapy for up to 12 cycles of toral therapy
 - ii. Arm B: R-Len 20mg, Days 1-21, cycles 1-12,rituximab 375mg/m2, Days 1,8,15,and 22 in cycle 1; Day 1 in cycles 2-5
 - iii. Arm B: R-Len 20mg, Days 1-21, cycles 1-12,rituximab 375mg/m2, Days 1,8,15,and 22 in cycle 1; Day 1 in cycles 2-5
 - iv. Arm C: R-CHOP 6 cycles
- 7. Relapsed and Refractory Follicular or Marginal Zone Lymphoma
- 8. Diffuse Large Cell, First Line
- 9. Mantle Cell Lymphoma

Open 8/13/25

Accrual Goal = 3

CNS (C71)

- 1. Glioblastoma Multiforme

Leukemia (C91-C92)

- 1. CLL, First Line
- 2. CLL, Relapsed or Refractory
- 3. CML

Myeloma (C90)

- 1. 1st Line
- 2. Relapsed / Refractory 1-3 Lines
- 3. Relapsed / Refractory > or equal to 2 Lines

MDS (D46)

- 1. 1st Line
- 2. Observational Registry

Unknown Primary (199)

- 1. 1st Line

Other

- 1. Tissue Studies
- 2. Observational Studies

Multiple Sites

- 1. Phase I
- 2. EMD MS100070-0176 (EMR100070-001 Rollover)
- 3. Novartis Signature Series
- 4. Solid Tumors, Refractory
- 5. Solid Tumors, Advanced or Metastatic

Supportive Care

- 1. Bone Mets
- 2. Anemia
- 3. Thrombocytopenia

this list was last updated on: 10/20/25